# Relationship Between Body Composition and Biomarkers in Adult Females with Breast Cancer: 1-Year Follow-Up Prospective Study

**Authors:** Angélica Larrad-Sáinz, María Gemma Hernández Núñez, Ana Barabash Bustelo, Inés Gil Prados, Johanna Valerio, José Luis Espadas Gil, María Eugenia Olivares Crespo, María Herrera de la Muela, Blanca Bernaldo Madrid, Irene Serrano García, Ignacio Cristóbal García, Miguel Ángel Rubio-Herrera, Alfonso Luis Calle-Pascual, Juana María Brenes Sánchez, Pilar Matía-Martín

PMC · DOI: 10.3390/nu17152487 · 2025-07-30

## TL;DR

This study found that breast cancer patients experience increased fat and reduced muscle after one year, changes not captured by traditional measures.

## Contribution

The study uses BIA and US to detect body composition changes in breast cancer patients, revealing sarcopenic obesity and metabolic correlations.

## Key findings

- Fat mass increased while skeletal muscle mass and strength decreased after one year of treatment.
- Sarcopenic obesity prevalence rose from 1.16% to 4.9% in the study group.
- Fat parameters correlated positively with insulin, HOMA-IR, and triglycerides, and negatively with HDL-cholesterol.

## Abstract

Background/Objectives: After diagnosis, it is common for women with breast cancer to gain weight, which is associated with worse clinical outcomes. However, traditional measures such as body weight, BMI, and waist circumference do not detect key changes in body composition, such as fat redistribution or muscle loss. The objective of this exploratory study was to assess the evolution of body composition and muscle strength after one year of treatment, and their relationship with metabolic biomarkers. Methods: Prospective observational study in newly diagnosed breast cancer patients. Body composition was assessed using bioelectrical impedance analysis (BIA) and ultrasound (US); muscle strength was measured by handgrip dynamometry. Biomarkers analyzed included glucose, insulin, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), glycosylated hemoglobin (HbA1c), total cholesterol (and its fractions), triglycerides, C-reactive protein (CRP), 6-interleukin (IL-6), vitamin D, myostatin, and fibroblast growth factor 21 (FGF-21). Results: Sixty-one women (mean age 58 years) were included. After one year, fat mass and related parameters significantly increased, while skeletal muscle mass and muscle strength decreased. Sarcopenic obesity prevalence rose from 1.16% to 4.9%. No significant changes were found in biomarkers, but positive correlations were observed between fat parameters and insulin, HOMA-IR, and triglycerides, and negative correlations with HDL-cholesterol. Conclusions: BIA and US can detect unfavorable changes in body composition that are not reflected in conventional measurements. At one year post-diagnosis, women showed increased fat accumulation, muscle loss, and reduced strength, even without significant metabolic biomarker changes. Further research is warranted to elucidate the long-term clinical implications of these findings and the external validity in larger cohorts.

## Linked entities

- **Proteins:** LOC5521725 (growth/differentiation factor 8)
- **Chemicals:** glucose (PubChem CID 5793), insulin (PubChem CID 70678557)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** FGF21 (fibroblast growth factor 21) [NCBI Gene 26291], CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, MSTN (myostatin) [NCBI Gene 2660] {aka GDF8, MSLHP}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** muscle loss (MESH:D009135), Insulin Resistance (MESH:D007333), Sarcopenic obesity (MESH:D009765), Breast Cancer (MESH:D001943), fat (MESH:D004620)
- **Chemicals:** cholesterol (MESH:D002784), triglycerides (MESH:D014280), glucose (MESH:D005947), vitamin D (MESH:D014807)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12348593/full.md

---
Source: https://tomesphere.com/paper/PMC12348593